Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 2/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | ALKBH1 | Q13686 | 2/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18031279 | 0.86 | PTGER1 (0.58) | PTGER1MCL1ALDH1A1KMT2AFOLH1 | |
| SCHEMBL30593169 | 0.86 | PTGER1 (0.58) | PTGER1MCL1ALDH1A1KMT2AFOLH1 | |
| SCHEMBL7864058 | 0.85 | ALDH1A1 (0.43) | PTGER1MCL1ALDH1A1BAK1NAAA | |
| SCHEMBL7866706 | 0.78 | MEN1 (0.39) | ALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL8668088 | 0.76 | ALDH1A1 (0.66) | PTGER1ALDH1A1KMT2APTK2BFOLH1 | |
| SCHEMBL26984529 | 0.75 | MCL1 (0.50) | PTGER1MCL1ALDH1A1FOLH1NPC1 | |
| SCHEMBL31467060 | 0.75 | MCL1 (0.50) | PTGER1MCL1ALDH1A1FOLH1NPC1 | |
| SCHEMBL8667447 | 0.75 | ALDH1A1 (0.64) | PTGER1ALDH1A1KMT2APTK2BFOLH1 | |
| SCHEMBL5252361 | 0.74 | FOLH1 (0.52) | PTGER1MCL1ALDH1A1KMT2AFOLH1 | |
| SCHEMBL21679225 | 0.74 | RAB9A (0.54) | ALDH1A1KMT2AALKBH1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2527338-B1 | N5-(2-ETHOXYETHYL)-N3-(2-PYRIDINYL) -3,5-PIPERIDINEDICARBOXAMIDE DERIVATIVES FOR USE AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| US-8497286-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| US-8497286-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| US-8383650-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | disclosed |
| US-8383650-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | disclosed |
| US-20130005770-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2013-01-03 | — | — | US | disclosed |
| US-20130005770-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2013-01-03 | — | — | US | disclosed |
| WO-2009000811-A1 | N5-(2-ETHOXYETHYL)-N3-(2-PYRIDINYL)-3,5-PIPERIDINEDICARBOXAMIDE DERIVATIVES FOR USE AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2008-12-31 | — | — | WO | disclosed |
| US-20080319018-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20080319018-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319018-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | PTGER1 113/4885MCL1 4548/4885ALDH1A1 114/4885 |
| US-20130005770-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | PTGER1 113/4885MCL1 4548/4885ALDH1A1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.